Healthlynked Financials
Healthlynked (HLYK) reported $2.1M in revenue for fiscal year 2025, down 31.3% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 10 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
HealthLynked is using overhead cuts to slow cash drain, but the business still runs on external financing today.
Between FY2023 and FY2025, operating cash flow moved from-$4.1M to-$1.7M . But revenue still fell from$5.7M to$2.1M , and lower selling/admin suggests the better cash profile came from retreating overhead rather than a stronger demand engine inside the business.
The balance sheet now shows negative equity of
FY2025 net loss of
Financial Health Signals
Healthlynked does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Healthlynked scores -47.64, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($8.1M) relative to total liabilities ($7.5M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Healthlynked passes 2 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 2 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), neither operating efficiency signal passes.
Healthlynked reported a net loss of $3.3M while operations used $1.7M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Healthlynked generated $2.1M in revenue in fiscal year 2025. This represents a decrease of 31.3% from the prior year.
Healthlynked's EBITDA was -$2.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 54.2% from the prior year.
Healthlynked reported -$3.3M in net income in fiscal year 2025. This represents an increase of 46.5% from the prior year.
Healthlynked earned -$1.16 per diluted share (EPS) in fiscal year 2025. This represents an increase of 46.8% from the prior year.
Cash & Balance Sheet
Healthlynked held $37K in cash as of fiscal year 2025; long-term debt is not reported for that period.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Margins & Returns
Not reported for fiscal year 2025.
Not shown for fiscal year 2025: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not shown for fiscal year 2025: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not reported for fiscal year 2025.
Capital Allocation
None of these metrics is reported for fiscal year 2025.
HLYK Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.4M | $2.1M-31.3% | $3.0M-47.4% | $5.7M-2.3% | $5.9M-9.8% | $6.5M+5.9% | $6.1M+52.6% | $4.0M+77.9% | $2.3M+7.4% | $2.1M | N/A |
| SG&A Expenses | $2.3M | $2.0M-33.0% | $3.0M-16.1% | $3.6M-20.8% | $4.6M-7.1% | $4.9M+60.9% | $3.1M+5.1% | $2.9M+2.5% | $2.8M+53.9% | $1.8M+19.8% | $1.5M |
| Operating Income | -$2.3M | -$2.1M+54.8% | -$4.7M-12.7% | -$4.2M+52.1% | -$8.7M-62.4% | -$5.3M-73.5% | -$3.1M+4.3% | -$3.2M-8.0% | -$3.0M-65.9% | -$1.8M-52.5% | -$1.2M |
| Interest Expense | N/A | N/A | N/A | $21K | $0 | N/A | N/A | $244K+26.4% | $193K+93.8% | $100K+172.1% | $37K |
| Net Income | -$4.0M | -$3.3M+46.5% | -$6.1M-505.8% | -$1.0M+88.5% | -$8.8M+15.3% | -$10.4M-80.9% | -$5.8M-4.1% | -$5.5M+4.5% | -$5.8M-124.4% | -$2.6M-87.5% | -$1.4M |
| EPS (Diluted) | — | -$1.16+46.8% | -$2.18 | $0.00+100.0% | -$0.04+20.0% | -$0.05-25.0% | -$0.04 | -$0.06+14.3% | -$0.07-75.0% | -$0.04-100.0% | -$0.02 |
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, R&D Expenses, Income Tax.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
HLYK Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $1.7M-23.4% | $2.2M-48.1% | $4.3M-6.6% | $4.6M-57.2% | $10.7M+33.2% | $8.0M+215.2% | $2.5M+495.9% | $427K-2.8% | $440K+33.5% | $330K |
| Current Assets | $1.6M-5.5% | $1.6M+150.1% | $656K-69.4% | $2.1M-41.3% | $3.7M+804.6% | $404K+0.2% | $403K+7.3% | $375K+2.3% | $367K+47.3% | $249K |
| Cash & Equivalents | $37K-51.3% | $76K-69.2% | $247K+299.4% | $62K-98.1% | $3.3M+1929.6% | $162K+46.9% | $110K-18.7% | $136K+171.5% | $50K-14.8% | $59K |
| Inventory | $18K-59.8% | $45K-66.5% | $133K-30.9% | $193K+42.9% | $135K+41.7% | $95K+35.1% | $70K | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | $21K-71.1% | $72K-16.2% | $86K-1.0% | $87K+4.7% | $83K-27.5% | $115K+1.4% | $113K-22.8% | $147K |
| Goodwill | N/A | N/A | N/A | $320K-58.2% | $766K-33.3% | $1.1M+1497.6% | $72K | N/A | N/A | N/A |
| Total Liabilities | $7.5M+39.5% | $5.4M+54.0% | $3.5M-18.5% | $4.3M+22.2% | $3.5M-47.7% | $6.7M+23.9% | $5.4M+60.3% | $3.4M+35.0% | $2.5M+100.7% | $1.2M |
| Current Liabilities | $7.0M+49.5% | $4.7M+94.4% | $2.4M-30.6% | $3.5M+81.2% | $1.9M-60.7% | $4.9M-0.5% | $4.9M+46.1% | $3.4M+36.0% | $2.5M+156.1% | $964K |
| Long-Term Debt | N/A | N/A | N/A | $45K-55.6% | $101K+464.3% | $18K | N/A | $3K-85.7% | $21K-46.2% | $40K |
| Total Equity | -$5.8M-84.1% | -$3.1M-488.9% | $805K+155.9% | $314K-95.6% | $7.2M+433.6% | $1.4M+147.5% | -$2.8M+3.1% | -$2.9M-43.1% | -$2.1M-125.0% | -$912K |
| Retained Earnings | -$50.5M-4.9% | -$48.2M-14.6% | -$42.0M-2.5% | -$41.0M-27.4% | -$32.2M-47.8% | -$21.8M-35.9% | -$16.0M-52.6% | -$10.5M-123.2% | -$4.7M-121.5% | -$2.1M |
HLYK Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$1.4M | -$1.7M+51.0% | -$3.5M+15.7% | -$4.1M+5.0% | -$4.4M-15.7% | -$3.8M-78.1% | -$2.1M+10.4% | -$2.4M-0.3% | -$2.4M-45.5% | -$1.6M-114.1% | -$756K |
| Capital Expenditures | N/A | N/A | $3K+73.2% | $2K-93.6% | $24K+22.4% | $19K-23.0% | $25K+148.6% | $10K+235.0% | $3K-81.4% | $16K+28.0% | $13K |
| Free Cash Flow | N/A | N/A | -$3.5M+15.7% | -$4.1M+5.5% | -$4.4M-15.8% | -$3.8M-76.9% | -$2.1M+9.7% | -$2.4M-0.6% | -$2.4M-44.3% | -$1.6M-112.7% | -$769K |
| Investing Cash Flow | N/A | $125K-70.4% | $422K-88.0% | $3.5M+743.6% | -$545K-59.6% | -$341K-118.8% | $1.8M+481.5% | -$475K-15724.7% | -$3K+81.4% | -$16K-28.0% | -$13K |
| Financing Cash Flow | $1.3M | $1.5M-46.6% | $2.9M+252.0% | $824K-50.9% | $1.7M-76.8% | $7.2M+1929.3% | $357K-87.3% | $2.8M+15.0% | $2.4M+50.3% | $1.6M+103.9% | $798K |
| Dividends Paid | N/A | $0 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | $8K | N/A | $1K | N/A | N/A | N/A |
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
HLYK Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -102.3% | -155.5% | -72.5% | -147.8% | -82.0%-32.0pp | -50.1%+29.8pp | -79.8% | -131.6% | -85.2% | N/A |
| Net Margin | -158.8% | -203.8% | -17.7% | -150.5% | -160.3% | -93.8% | -137.6% | -256.3% | -122.7% | N/A |
| Return on Equity | N/A | N/A | -125.8%+2677.8pp | -2803.5%-2659.0pp | -144.5%+281.8pp | -426.3% | N/A | N/A | N/A | N/A |
| Return on Assets | -192.7%+83.1pp | -275.8%-252.2pp | -23.6%+168.8pp | -192.5%-95.1pp | -97.4%-25.7pp | -71.7%+145.4pp | -217.1%+1137.9pp | -1355.0%-768.1pp | -586.9%-169.2pp | -417.7% |
| Current Ratio | 0.22-0.1x | 0.35+0.1x | 0.27-0.3x | 0.62-1.3x | 1.90+1.8x | 0.080.0x | 0.080.0x | 0.110.0x | 0.15-0.1x | 0.26 |
| Debt-to-Equity | N/A | N/A | 4.32+4.2x | 0.14+0.1x | 0.010.0x | 0.01 | N/A | N/A | N/A | N/A |
| FCF Margin | N/A | -116.2% | -72.5%+2.4pp | -74.9%-16.6pp | -58.3%-23.4pp | -34.9%+24.1pp | -59.0% | -104.4% | -77.7% | N/A |
Not reported in any period shown, so not listed: Gross Margin.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Note: Shareholder equity is negative (-$5.8M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.22), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Where Healthlynked Ranks
Frequently Asked Questions
What is Healthlynked's annual revenue?
Healthlynked (HLYK) reported $2.1M in total revenue for fiscal year 2025. This represents a -31.3% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Healthlynked's revenue growing?
Healthlynked (HLYK) revenue declined by 31.3% year-over-year, from $3.0M to $2.1M in fiscal year 2025.
Is Healthlynked profitable?
No, Healthlynked (HLYK) reported a net income of -$3.3M in fiscal year 2025.
What is Healthlynked's EBITDA?
Healthlynked (HLYK) had EBITDA of -$2.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Healthlynked's operating cash flow?
Healthlynked (HLYK) recorded an outflow of $1.7M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Healthlynked's total assets?
Healthlynked (HLYK) had $1.7M in total assets as of fiscal year 2025, including both current and long-term assets.
What is Healthlynked's current ratio?
Healthlynked (HLYK) had a current ratio of 0.22 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.
What is Healthlynked's return on assets (ROA)?
Healthlynked (HLYK) had a return on assets of -192.7% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Healthlynked's cash runway?
Based on fiscal year 2025 data, Healthlynked (HLYK) had $37K in cash against an annual operating cash burn of $1.7M. This gives an estimated cash runway of approximately 0 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
Why is Healthlynked's debt-to-equity ratio negative or not reported?
Healthlynked (HLYK) has negative shareholder equity of -$5.8M as of fiscal year 2025, so no debt-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is Healthlynked's Altman Z-Score?
Healthlynked (HLYK) has an Altman Z-Score of -47.64, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Healthlynked's Piotroski F-Score?
Healthlynked (HLYK) has a Piotroski F-Score of 2 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Healthlynked's earnings high quality?
Healthlynked (HLYK) reported a net loss of $3.3M while operations used $1.7M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.